TIGER'S TAKE: On our trading list. HUGE OPTIONS VOLUME again TODAY! Down big after pricing a secondary offering/dilution at $18.00 a share. This is a good biotech name for trading and for the longer term. We would use the latest weakness to buy some stock or calls, or sell puts. $AMRN Amarin 22.222M share Secondary priced at $18.00 JPMorgan, Goldman Sachs, Jefferies and Cantor Fitzgerald acted as joint book running managers for the offering. $AMRN, Amarin Corporation plc / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page.